Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
ASML Holding NV: A Significant Exit in Mark Hillman's Q1 2026 Portfolio Adjustments
07:02am, Friday, 15'th May 2026
Exploring the Strategic Moves of a Seasoned Investor Mark Hillman (Trades, Portfolio) recently submitted the 13F filing for the first quarter of 2026, providin
HSBC, BP and GSK combine in dividend-driven knock to Footsie
04:29am, Thursday, 14'th May 2026
A clutch of heavyweight dividend payments knocked almost 20 points off the FTSE 100 on Thursday, with four of the index's biggest companies trading ex-dividend. HSBC Holdings PLC (LSE:HSBA) had the l
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment
02:28am, Monday, 11'th May 2026
GSK on Monday said it had entered into a strategic collaboration with Hong Kong-listed Sino Biopharmaceutical to accelerate the launch of its hepatitis B trea
Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults
08:00am, Thursday, 07'th May 2026
PHILADELPHIA--(BUSINESS WIRE)-- #Adolescents--Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults.
The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat
08:45am, Saturday, 02'nd May 2026
Earnings season is in full swing, and on April 29, three Big Pharma mainstays reported Q1 2026 earnings. Investors were looking for strong results—and strong guidance—that could serve as a sorely
Why GSK (GSK) is a Top Value Stock for the Long-Term
10:40am, Thursday, 30'th Apr 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
JP Morgan retains 'underweight' on GSK with £17 price target as earnings upgrade potential seen as limited
10:32am, Thursday, 30'th Apr 2026
Bank sits 5-10% below consensus on core earnings from 2027, citing need for pipeline success and new launch execution JP Morgan has retained its underweight...
JP Morgan retains 'underweight' on GSK with £17 price target as earnings upgrade potential seen as limited
09:46am, Thursday, 30'th Apr 2026
Bank sits 5-10% below consensus on core earnings from 2027, citing need for pipeline success and new launch execution JP Morgan has retained its underweight rating on GSK PLC (LSE:GSK, NYSE:GSK) with
Ideal Power to host Q1 2026 earnings conference call on May 14
05:49am, Thursday, 30'th Apr 2026
Ideal Power Inc (NASDAQ:IPWR, FRA:5ILA), developer of its B-TRAN bidirectional semiconductor power switch, said management will host a conference call on...
OTC Markets Group adds Charlotte’s Web to OTCQX Best Market
05:36am, Thursday, 30'th Apr 2026
OTC Markets Group Inc. (OTCQX:OTCM) announced that Charlotte’s Web Holdings, a botanical wellness innovation company, has qualified to trade on the OTCQX...
GSK plc (GSK) Q1 2026 Earnings Call Transcript
03:01pm, Wednesday, 29'th Apr 2026
GSK plc (GSK) Q1 2026 Earnings Call Transcript
GSK Q1 Earnings Beat Estimates, Specialty Medicines Drive Sales Growth
11:31am, Wednesday, 29'th Apr 2026
GSK Q1 earnings and revenues beat estimates as Specialty Medicines lifted sales, with HIV, oncology and respiratory growth. The guidance for 2026 remains unchanged.
GSK (GSK) Tops Q1 Earnings and Revenue Estimates
08:10am, Wednesday, 29'th Apr 2026
GSK (GSK) came out with quarterly earnings of $1.24 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.13 per share a year ago.
UK's biggest drugmakers see surprise profit bump, even as pharma grapples with U.S. policies
05:32am, Wednesday, 29'th Apr 2026
Britain's largest drugmakers saw 2026 get off on a positive note, with AstraZeneca and GSK both reporting core earnings ahead of expectations on Wednesday The CEOs of a number of European pharma giant
GSK reaffirms 2026 guidance after strong first-quarter performance
03:04am, Wednesday, 29'th Apr 2026
GSK PLC (LSE:GSK, NYSE:GSK), the FTSE 100 pharmaceuticals giant, has reiterated its full-year 2026 guidance after delivering a strong first quarter, with core operating profit growth and earnings per
